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Abstract
Background:  Dietary fatty acids may modulate inflammation in macrophages of the
atherosclerotic plaque, affecting its stability. The n-6 polyunsaturated fatty acid (PUFA) arachidonic
acid (AA) generally promotes inflammation, while the PUFAs of the n-3 series eicosapentaenoic
acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA) are considered anti-
inflammatory. We determined how these PUFAs influence MMP-9 expression and secretion by the
human monocytic cell line (MonoMac 6) at baseline and after 24-hour exposure. MMP-9 protein
was measured by zymography and relative lev e l s  o f  M M P - 9  m R N A  w e r e  d e t e r m i n e d  u s i n g
quantitative real time PCR.
Results: Supplementation with AA (but not the n-3 fatty acids) increased, in a dose-dependent
manner, expression of MMP-9 protein. This stimulation was regulated at the mRNA level. MMP-9
secretion started after 1 h of incubation and could not be prevented by simultaneous presence of
n-3 series fatty acids. Finally, the secretion could be attenuated by LY 294002, a specific
phosphatidylinositol-3-kinase (PI3K) inhibitor and by SH-5, a selective Akt inhibitor, suggesting that
activation of PI3K by AA leads to augmented and sustained MMP-9 production.
Conclusion: This study shows that of the PUFA studied, AA alone influences the expression of
MMP-9, which might have implications in MMP-9 induced plaque rupture.
Background
Dietary fatty acids are known to modulate the metabolism
of lipids and lipoproteins and therefore also to be
involved in cardiovascular and metabolic diseases [1,2].
Dietary polyunsaturated fatty acids (PUFA) are classified
into two families, the n-6 and n-3 series. Although both
families are substrates for the same enzymes in many cel-
lular processes, the affinity of enzymes is greater for the n-
3 family than that for the n-6 family. As an example, ara-
chidonic acid (20:4n-6, AA), a metabolite of linoleic acid
(18:2n-6), is the substrate of cyclooxygenases and lipoxy-
genases in the production of potent inflammatory eicosa-
noids. The polyunsaturated fatty acids of the n-3 series
(eicosapentaenoic acid 20:5n-3, EPA; docosapentaenoic
acid 22:5n-3, DPA; and docosahexaenoic acid 22:6n-3,
DHA) limit the synthesis of these mediators from AA, and
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enhance the synthesis of less inflammatory eicosanoids
from EPA [3]. Recent studies have identified novel groups
of powerful EPA and DHA derived anti-inflammatory
mediators which are produced during the resolving phase
of an acute inflammatory response [4].
The propensity of atherosclerotic plaques to rupture is
influenced by their lipid content and the distribution of
lipid within the plaque as well as by the extent of infiltra-
tion of macrophages at the shoulder regions of the plaque
and by the thickness of the fibrous cap [5]. A thin fibrous
cap and a substantial presence of macrophages and other
inflammatory cells in the shoulder region indicate a vul-
nerable plaque likely to rupture. Matrix metalloprotein-
ases (MMPs) are a group of enzymes whose major
functions are directed toward remodelling of extracellular
matrix (ECM) components. Gelatinase B (MMP-9) is a
very complex enzyme in terms of domain structure or reg-
ulation of its activity and expression. MMP-9 activity is
controlled at different levels: transcriptional activation of
the gene by cytokines and other factors, activation of the
pro-enzyme by various enzymes like serine proteases and
regulation by specific tissue inhibitors of the matrix met-
alloproteinases (TIMPs). MMP-9 has been shown to be
up-regulated in unstable angina pectoris. It is mainly
expressed by macrophages located especially in vulnera-
ble regions of the atherosclerotic plaque [6]. Published
results thus suggest that localized increase in MMP-9 asso-
ciated with an inflammatory process in the vascular wall
has the potential to weaken the tissue structure thus
increasing the risk for plaque rupture. Still, the signalling
pathways that lead to induction of expression of MMP-9
are incompletely understood.
Dietary n-3 fatty acids have a variety of anti-inflammatory
and immuno-modulating effects that may be of relevance
to atherosclerosis and its clinical manifestations of myo-
cardial infarction, sudden death and stroke [1]. There is
epidemiological evidence that consumption of fish or n-3
PUFA protects against cardiovascular disease [7]. How-
ever, more critical meta-analyses regarding the clinical
importance of n-3 PUFA have also demonstrated no clear
effect on combined cardiovascular events [8]. The effects
of n-3 PUFA have been variously ascribed to anti-arrhyth-
mic or anti-thrombotic actions of n-3 PUFA but might as
well be linked to their anti-inflammatory effects [1]. Some
of these effects are brought about through modifications
in gene expression since long chain fatty acids also serve
as ligands for several nuclear transcription factors [9]. In a
recent study, patients who were scheduled to carotid
endarterectomy were randomly allocated to receive either
placebo, sunflower oil or fish oil. It was shown that the n-
3 PUFAs were readily incorporated into plaques and were
associated with reduced numbers of macrophages and
signs of inflammation [10]. Inflammatory prostaglandins
and leukotrienes derived from arachidonic acid have pre-
viously been shown to induce MMP production [11-13].
Human MonoMac 6 monocytes appear to be a useful cel-
lular model to investigate effects of compounds on plaque
vulnerability through MMP-9 activity [14]. In this study
we sought to clarify relationships between arachidonic
acid and the polyunsaturated n-3 fatty acids in regulation
of MMP-9.
Results
To investigate the impact of long chain fatty acids with dif-
ferent characteristics on MMP-9 secretion we incubated
MonoMac 6 cells in the presence of 1 μM and 10 μM AA,
EPA or DPA (Fig. 1A). The secretion of MMP-9 to the
medium increased in the presence of 1 μM AA as shown
by the greater activity of MMP-9 in zymography (2.3 ±
0.2-fold, n = 10) and was further enhanced by 10 μM AA
(6.7 ± 1.0-fold, n = 14). EPA and DPA had no effect, nei-
ther did DHA (result not shown). The effect of PMA (1.3
nM), a known activator of monocytes and also of MMP-9
secretion [15] was about ten-fold greater than that of 10
μM arachidonic acid Addition of 1 μM and 10 μM AA, EPA
or DPA along with PMA did not affect MMP-9 production
(Fig. 1B).
Effect of polyunsaturated fatty acids and PMA on the produc- tion of MMP-9 Figure 1
Effect of polyunsaturated fatty acids and PMA on the 
production of MMP-9. MonoMac 6 cells (0.8 × 106/ml in 
serum-free medium X-Vivo 15) were stimulated with 1 or 10 
μM arachidonic acid (AA), eicosapentaenoic acid (EPA) or 
docosapentaenoic acid (DPA) without (1A) or in the pres-
ence of 1.3 nM PMA (1B). The culture media were harvested 
after 24 h incubation and analysed for MMP-9 by gelatin 
zymography. The media of PMA-treated cells were diluted 
(1:10) to preserve the linearity of response in image analysis.Lipids in Health and Disease 2009, 8:11 http://www.lipidworld.com/content/8/1/11
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Fatty acid analysis of the cells showed that all the long
chain polyunsaturated fatty acids were readily taken up by
the cells and metabolized further. The amount of AA in
cellular lipids increased in the presence of 1 μM AA from
1.3 ± 0.037 μg/1.0 × 106 cells to 2.2 ± 0.23 μg/1.0 × 106
cells, and in the presence of 10 μM AA to 7.4 ± 1.29 μg/1.0
× 106 cells. In addition, fatty acid analysis showed that AA
was efficiently elongated to 22:4n-6. Similarily, EPA was
taken up by the cells and was elongated to 22:5n-3, since
the amount of this fatty acid increased from 0.5 ± 0.046
μg/1.0 × 106 cells to 2.2 ± 0.28 μg/1.0 × 106 cells when the
cells were exposed to 10 μM EPA for 24 h. Furthermore,
when the monocytes were incubated in the presence of
DPA this fatty acid was metabolized to 22:6n-3, which
was further retroconverted to EPA. These results show that
the fatty acids were taken up and were available at least to
the enzymes in endoplasmic reticulum and peroxisomes.
We then looked at the concentration-dependency of ara-
chidonic acid-induced secretion of MMP-9. We incubated
MonoMac-6 cells for 24 h in the presence of increasing
concentrations of AA (0–40 μM). Analysis of the zymo-
grams by image analysis gave a logarithmic dose response
curve (Fig. 2A). Examination of the cells after incubation
in the presence of 40 μM AA revealed large clumps of clus-
tered cells. This phenomenon was associated with a
slightly lowered cellular protein concentration suggesting
some undesirable effects of higher concentrations of AA
on cellular well-being.
To investigate the time course of AA-induced MMP-9
secretion we took small samples of medium at 1, 2, 4, 8,
16 and 24 h after adding 10 μM AA or 1.3 nM PMA. MMP-
9 activity became evident in zymograms of the media after
6 h to 8 h incubation with AA but was already discernible
after 4 h incubation with PMA. We then pre-exposed the
cells to 10 μM AA for different periods of time after which
the medium was discarded. The incubation was then car-
ried on with culture medium without AA for 24 h for
MMP-9 activity to be detectable in zymograms. As shown
in Fig. 2B, MMP-9 activity was augmented already after 1
h incubation with AA and increased for at least 6 h.
Since EPA, DPA or DHA by themselves had no effect on
MMP-9 secretion, we looked at their effect on AA-induced
production of MMP-9. Co-incubation of 5 μM AA with
increasing concentrations of EPA, DPA or DHA for 24 h
did not diminish or increase the secretion of MMP-9 (Fig.
3).
We then tested the hypothesis that AA could increase the
secretion of MMP-9 by modulating its gene expression. In
Fig 4 we show that MMP-9 mRNA expression was
increased 6- to 8-fold when stimulated with 10 μM AA for
24 h; it was only slightly up-regulated in the presence of
n-3 fatty acids and 1 μM AA (Fig. 4). Predictably, PMA
treatment stimulated MMP-9 expression to a much greater
extent than 10 μM AA (results not shown).
In an endeavour to understand further the mechanism
through which arachidonic acid acts, we investigated
whether it affected the activity of phosphatidylinositol 3-
Dose- and time-dependent stimulation of MMP-9 secretion  by arachidonic acid Figure 2
Dose- and time-dependent stimulation of MMP-9 
secretion by arachidonic acid. 2A. MonoMac 6 cells (0.8 
× 106 cells/ml in X-Vivo 15) were treated for 24 h with 
increasing concentrations of arachidonic acid. The media 
were collected and analysed for MMP-9 by zymography. Data 
are shown as means ± SEM of 3 to 4 independent experi-
ments. The increase of MMP-9 secretion was statistically sig-
nificant from 2.5 μM AA and upwards. 2B. MonoMac 6 cells 
(0.8 × 106 cells/ml in X-Vivo 15) were pre-exposed to 10 μM 
arachidonic acid for 1, 2, 4 or 6 hours where after the cul-
ture medium was changed to X-Vivo without arachidonic 
acid for 24 h. The media were analysed for MMP-9 by zymog-
raphy. Results are shown as means ± SEM of three independ-
ent experiments. A statistically significant increase in MMP-9 
secretion was evident after 1 h preincubation in comparison 
with cells incubated in the presence of vehicle only.Lipids in Health and Disease 2009, 8:11 http://www.lipidworld.com/content/8/1/11
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kinase (PI3K). For this end we incubated MonoMac 6 cells
with LY 294002, an inhibitor of PI3K for 30 min before
adding 10 μM AA or 1.3 nM PMA for 24 h. As shown in
Fig 5, Ly 294002 blocked the induction of MMP-9 by AA
and PMA in a dose-dependent manner. However, if the
inhibitor was removed from the incubation medium
Effect of docosapentaenoic acid (DPA) on arachidonic acid  (AA) stimulated production of MMP-9 Figure 3
Effect of docosapentaenoic acid (DPA) on arachi-
donic acid (AA) stimulated production of MMP-9. 
MonoMac 6 cells (0.8 × 106 cells/ml in X-Vivo 15) were incu-
bated in the presence of 5 μM arachidonic acid and increasing 
concentrations of DPA (1, 5, 10 μM) for 24 h. The presence 
of MMP-9 activity in the media was determined using zymog-
raphy.
Effect of polyunsaturated fatty acids on MMP-9 mRNA  expression Figure 4
Effect of polyunsaturated fatty acids on MMP-9 
mRNA expression. MonoMac 6 cells (4 × 106 cells/5 ml X-
Vivo 15 on Nunclon 60 mm dishes) were treated with 1 or 
10 μM arachidonic acid (AA), eicosapentaenoic acid (EPA) or 
docosapentaenoic acid (DPA) for 24 h. Then the cells were 
pelleted by centrifugation (400 × G, +4°C) and washed with 
ice-cold PBS. Total cellular RNA was isolated, reverse tran-
scribed and the resulting cDNA was amplified as described in 
the methods. The MMP-9 expression was demonstrated by 
real-time PCR. Results represent the means ± SEM of four 
independent experiments. Only 10 μM AA increased the 
expression of MMP-9 mRNA statistically significantly.
Inhibition of arachidonic acid (AA) and PMA induced stimula- tion of MMP-9 secretion by LY294002 Figure 5
Inhibition of arachidonic acid (AA) and PMA induced 
stimulation of MMP-9 secretion by LY294002. Dose- 
and time-dependent stimulation of MMP-9 secretion 
by arachidonic acid. MonoMac 6 cells (0.8 × 106 cells/ml in 
X-Vivo 15) were treated with various concentrations of 
LY294002 in DMSO for 30 min. Then 10 μM arachidonic acid 
(5A) or 1.3 nM PMA (5B) was added and the incubation was 
continued for 24 h. The media were analysed for the pres-
ence of MMP-9 using zymography and image analysis. Results 
(mean ± SEM) for 4 to 5 independent experiments are 
shown. All concentrations of LY294002 decreased the AA or 
PMA induced secretion of MMP-9 statistically significantly.Lipids in Health and Disease 2009, 8:11 http://www.lipidworld.com/content/8/1/11
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before the addition of AA or PMA the inhibitory effect was
lost. These results indicate a role for PI3K activation in the
signalling of both AA and PMA to produce MMP-9. To test
the phophatidylinositol signalling system downstream of
PI3K we treated the MonoMac 6 cells for 30 min with var-
ious concentrations of phosphatidyl inositol analog, SH-
5, an inhibitor of Akt. This was followed by stimulation of
the cells with 10 μM AA for 24 h. A concentration depend-
ent decrease of AA-induced MMP-9 secretion was seen in
zymographic analysis. The decrease was 20% (± 4%, n =
4) for 2.5 μM, 35% (± 3%, n = 4) for 5 μM and 53% (±
2%, n = 4) for 10 μM SH-5. These results further point to
phosphatidylinositol lipids as mediators of AA stimula-
tion.
Discussion
In the present study we show that incubation of human
leukaemia Mono Mac 6 cells in the presence of AA (20:4n-
6) in serum-free medium is associated with increased
secretion of MMP-9 to the growth medium in comparison
with control cells incubated without added AA. The
response was concentration-dependent and intensified
considerably as the level of AA rises from 1- to 40-μM.
Since the composition and content of cellular fatty acids
changed in accordance with fatty acids added to the incu-
bation medium, the fatty acids obviously entered the cells
either by diffusion or by membrane transport proteins. It
is possible that the effect of AA on MMP-9 secretion was
mediated via binding to a membrane receptor, since a
family of G-protein coupled free fatty acid receptors has
been recently identified [16]. However, none of these
receptors has been shown to be specific to arachidonic
acid.
EPA, DPA or DHA, fatty acids of the n-3 series, which are
considered to be anti-inflammatory, had no effect on
basal secretion of MMP-9. Since the n-3 series of polyun-
saturated fatty acids are known to compete for the same
enzymes as the n-6 series fatty acids in a multitude of cel-
lular processes, and the enzymes seem to prefer n-3 series,
we tested whether the effect of arachidonic acid on secre-
tion of MMP-9 could be controlled or even prevented by
increasing concentrations of EPA, DPA or DHA. However,
the AA-induced activity of MMP-9 did not diminish in the
presence of n-3 fatty acids, although the cellular fatty acid
content revealed an ample availability of n-3 fatty acids
after incubation. It is possible, though, that the intracellu-
lar pathways of n-6 and n-3 fatty acids differ in ways that
give advantage to AA [17,18]. On the other hand, it is also
possible that a prolonged exposure of cells to n-3 fatty
acids is necessary for inhibition of AA-triggered MMP-9
activity [19].
Experiments where MonoMac 6 cells were pre exposed to
AA for increasing periods of time (Fig. 2B) showed that
the system delivering MMP-9 to the medium was acti-
vated already after 1 h incubation and increased for at
least 6 h. Given that a quantity of pro-MMP-9 is stored in
intracellular vesicles it is possible that the activity detected
during the first hour of incubation was in fact due to
degranulation of existing vesicles. Degranulation of stor-
age vesicles has been shown to occur quickly in response
to less than 1 h treatment with IL-8 in neutrophils, where
the activity of MMP-9 increased 2.5-fold but then declined
[20]. It is not known whether AA causes degranulation in
MonoMac 6 cells, but the continued accumulation of
MMP-9 in the incubation medium speaks for additional
mechanisms. The increases in AA-induced secretion of
MMP-9 was blocked by co-treatment of MonoMac 6 cells
with 1–10 μM of the protein synthesis inhibitor cyclohex-
imide (data not shown), indicating further that the AA
effect requires de novo protein synthesis.
The transcriptional regulatory mechanism was confirmed
by the increase of MMP-9 mRNA by AA treatment. We
could show in repeated experiments that the expression
level of MMP-9 mRNA increased in response to AA,
whereas EPA or DPA did not produce such amplifications.
The response with AA was somewhat variable as can be
seen from Fig. 4, but it was well associated with the results
of enzyme activity as measured using zymography. It is
notable that the level of mRNA was persistently elevated
after 24-h incubation in the presence of the AA in compar-
ison with basal conditions.
Production of MMP-9 by macrophages has been shown to
occur through a prostaglandin E2/cAMP-dependent mech-
anism. It has been shown that production of MMP-9 is
induced by prostaglandin E2 (PGE2), the predominant
eicosanoid of macrophages [21]. PGE2 is produced from
AA by the coupled actions of cyclooxygenase and prostag-
landin E synthase [22]. Cylooxygenase 1 (COX-1) is con-
stitutively expressed but cyclooxygenase 2 (COX-2) is
induced by inflammatory cytokines, growth factors or
phorbol esters. PGE2 acts in an autocrine or paracrine
manner and activates adenylate cyclase. The increased
cAMP leads to activation of PKA, and the expression of
MMP-9 [23]. Studies using human monocytes have
shown that induction of COX-2 protein production and
concomitant PGE2 increase occur at 4 h – 16 h after stim-
ulation with LPS [24]. In contrast, in our experiments the
secretion of MMP-9 was enhanced after 1 h incubation in
AA containing medium, speaking for a faster mechanism.
Also, it has been shown that PGE2 alone does not stimu-
late MMP-9 synthesis in MonoMac 6 cells but needs a
simultaneous presence of an effective primary stimulus
such as TNFα [25].
The n-3 series fatty acids are competitive inhibitors of
cyclooxygenase-catalysed catabolism of AA and show aLipids in Health and Disease 2009, 8:11 http://www.lipidworld.com/content/8/1/11
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preference for the COX-2 over the COX-1 forms [26], but
could not prevent the effect of AA in our experiments.
Therefore, we felt that AA by itself could trigger the events
that lead to MMP-9 secretion. Earlier studies by Hii et al.
[27] have shown that AA or its metabolites can activate
PI3K-mediated pathways. On the other hand, studies of
Lu et al. [28] show that in LPS-activated human peripheral
blood monocytes MMP-9 production resulted through
the stimulation of PI3K signalling pathway. Indeed, when
we blocked the capability of PI3K to generate PIP3 in
MonoMac 6 cells by Ly 294002 (a specific inhibitor of
PI3K), MMP-9 production was inhibited in both AA and
PMA stimulated cells. The result indicates that the PI3K
pathway has a central role in regulation of monocyte
MMP-9 production following stimulation with AA. This
outcome accords with the results of Sato and co-workers,
where the secretion of MMP-9 could be prevented by
nobiletin (a flavonoid) or LY294002 in fibrosarcoma cells
[29]. Activation of PI3K leads to phosphorylation of inosi-
tol lipids, in response to activation and membrane trans-
location of Akt/Protein kinase B. Inhibition of Akt by SH-
5 was associated with attenuation of MMP-9 secretion in
AA stimulated MonoMac 6 cells. This result further points
to the involvement of PI3K signalling system in AA-
induced MMP-9 production. Activated Akt in turn phos-
phorylates several proteins that regulate cell survival,
including Bad and caspase 9 [30]. This activation is
important for monocyte survival and therefore the results
using PI3K or Akt inhibitors should be considered very
carefully. It is possible that MonoMac 6 cell viability was
affected and therefore the cells stopped secreting MMP-9.
However, no evidence of increased cell death could be
seen in Trypan Blue exclusion tests. MMP-9 production in
response to LPS-induced PI3K stimulation has also been
reported to occur through IKKα/NFκB pathway in human
monocytes [28]. Whether AA also acts through this path-
way remains to be examined.
AA concentrations in tissues and for example in inflam-
matory cells are dictated in part by the concentration of
AA that these cells are exposed to and partly by local for-
mation from linoleic acid [31]. AA is distributed to the
cells as albumin-bound FA or lysophospholipid and as a
component of various lipoprotein particles. Extracellular
and intracellular concentrations of free AA are kept low,
but in stressful situations like inflammation the extracel-
lular concentration of AA can reach up to a level of a hun-
dred  μM [32]. This means that the fatty acid
concentrations that were used in our in vitro incubations
were well within the in vivo range. The primary pathway
leading to AA release is the hydrolysis of phospholipids by
enhanced activity of either secretory or cytoplasmic phos-
pholipase A2. Relevant to the study of atherogenesis is the
finding in human THP-1 monocytes that native LDL elic-
ited a rapid, dose-dependent release of AA which was fur-
ther increased when LDL was modified by secretory
phospholipase A2 (PLA2) [33]. Also, it was recently
reported by Namgaladze et al. [34] that sPLA2-modified
LDL activated the PI3K pathway, thus increasing mono-
cyte survival. The active ingredient was shown to reside in
the lipid fraction and was suggested to be AA since this
fatty acid reproduced the effect. Our results further estab-
lish the important role of AA in intracellular communica-
tions system and as a pro-atherogenic factor by linking it
to the production of matrix degrading protease MMP-9 by
way of PI3K.
Conclusion
In summary, MonoMac 6 cells secreted MMP-9 in
response to increasing clinically relevant concentrations
of AA in the medium. The secretion increased due to
increased expression of MMP-9 mRNA. MMP-9 secretion
started fairly rapidly and could not be prevented by simul-
taneous presence of n-3 series fatty acids. The secretion
could be attenuated by LY 298002, a specific phosphati-
dylinositol-3-kinase inhibitor and by SH-5, a selective Akt
inhibitor, which suggests that activation of phosphatidyli-
nositol-3-kinase by AA leads to augmented and sustained
MMP-9 production.
Methods
Cell culture
MonoMac 6, an established human monocytic cell line
that grows in suspension, was obtained from the German
Collection of Microorganisms and Cell Cultures (DSMZ
ACC 124; Braunschweig, Germany). Cell cultures were
maintained in RPMI-1640 medium (BioWhittaker, Bel-
gium) supplemented with 2 mM L-glutamine, 5 ml/l non-
essential amino acids, penicillin (50 IU/ml), streptomycin
(100 μg/ml), 1 mM sodium pyruvate, 1 mM oxaloacetate,
0.2 U/ml bovine insulin (OPI Media Supplement, Sigma
Chemicals Co) and 10% heat-inactivated fetal bovine
serum (FBS). The cells were cultured at a density of 0.3 –
1 × 106 cells/ml in humidified 5% CO2 at 37°C. Fresh
medium was added to the cultures twice weekly replacing
one third of the suspension which was either reseeded or
discarded. For the experiments, cells were harvested,
washed with phosphate buffered saline (PBS), pH 7.4,
and seeded on 12-well Nunclon plates (Nunc A/S, Den-
mark) at 0.8 × 106 cells/ml in serum-free medium X-Vivo
15 (BioWhittaker, Belgium) supplemented with penicil-
lin-streptomycin. The cells were incubated in the presence
of indicated concentrations of fatty acids (AA, EPA, DPA,
DHA, all from Cayman Chemical), PMA (Sigma), LY
294002 (Cayman Chemical) or SH-5 (Alexis Biochemi-
cals) for 24 h unless otherwise stated. Cell viability was
checked with the Trypan Blue exclusion test. Cellular pro-
tein concentrations were determined by the method of
Lowry.Lipids in Health and Disease 2009, 8:11 http://www.lipidworld.com/content/8/1/11
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Zymography
Gelatin zymography was essentially done as described
[35]. Media from MonoMac 6 incubations were diluted in
electrophoresis sample buffer [36] and subjected to elec-
trophoresis in a 10% SDS-polyacrylamide gel embedded
with 1 mg/ml gelatin (Sigma) in nonreducing conditions.
We used the Mini-PROTEAN II apparatus at 4°C (Bio
Rad). After electrophoresis the enzymes were renatured
with two 30 min washes in 0.25% Triton X-100, and then
the enzyme reaction was allowed to proceed in activation
buffer (50 mM Tris-HCl, pH 7.5, containing 15 mM
CaCl2, 1 μM ZnCl2 and 1% Triton X-100) at 37°C for 18
h. Thereafter the gels were stained for 1.5 h with 0.1% (w/
v) Coomassie Brilliant Blue in 40% (v/v) isopropanol and
destained in 7% acetic acid for a minimum of 3 h. As a
molecular weight marker we used BenchMark™ Protein
Ladder from Invitrogen.
Image analysis
The degree of gelatin digestion was quantified using an
Epson Perfection 3200 Photo scanner interfaced to a com-
puter. Gels were scanned using Epson Scan software (ver-
sion 1.00E) in transparency option and gray scale mode.
The density of each pixel is encoded on a scale ranging
from 1 (clear) to 255 (opaque). The scanner was cali-
brated using the Stouffer Graphic Arts step tablet. The
images were analysed with Scion Image software (Scion
Corporation). The density measurements were linearized
using the Rodbard curve-fitting function within the Scion
Image program. The images were digitally inverted so that
integration of bands is reported as positive values. The
pixel density was determined after background density
subtraction and used to calculate the integrated density of
a selected band. The integrated density values of gelatino-
lytic activity of MMP-9 are reported in volume units of
pixel intensity per mm2 and adjusted for cellular protein
concentration.
RNA
Total RNA was isolated from fresh cells using a commer-
cial kit (Invitrogen Ltd, Paisley, UK). After isolation, RNA
was incubated with DNAse I to remove genomic DNA. To
determine the concentration and purity of RNA, the
absorbance was measured at 260 nm and 280 nm in a
spectrophotometer from an aliquot of the samples. Before
cDNA synthesis, the integrity and size distribution of total
RNA was checked by agarose gel electrophoresis and
ethidium bromide staining.
cDNA synthesis and RT-PCR
Total RNA was reverse transcribed to cDNA using TagMan
reverse transcription reagents (Roche Molecular Systems,
Inc, Branchburg, NJ, USA).
Relative quantification of MMP-9 mRNA levels was done
using real time PCR (AbiPrism 7000, Applied Biosystems,
Foster City, CA, USA) with TagMan Assays-on-demand
probe process (assay ID Hs00234579-m1). Eukaryotic
translation elongation factor (EEF-2) mRNA was used as
an endogenous RNA control (assay ID Hs00157330-m1).
Relative quantification of the target MMP-9 mRNA levels
in comparison to the reference gene EEF-2 (ratio) was cal-
culated using the comparative CT method. The results
were expressed as N-fold differences in MMP-9 expression
relative to EEF-2 expression.
Analysis of cellular fatty acid composition
All organic solvents were redistilled. Chloroform, metha-
nol, toluene (all analytic grade) were purchased from
Merck (Darmstadt, Germany). Petroleum spirit (b.p. 60–
69°C) was from Neste Oy (Finland).
The cells were stored under nitrogen at -70°C until analy-
sis. Lipids were extracted from approximately 1.2 × 106
cells with chloroform-methanol, partitioned, and the
chloroform phase was dried under N2 [37]. Tripentadeca-
noic acid was added as an internal standard. Saponifica-
tion of lipids was carried out by boiling in 33% KOH in
ethanol at 85°C for 2 h. The nonsaponifiable lipids were
extracted into petroleum spirit. The lower phase was acid-
ified with HCl, and the fatty acids were extracted into
petroleum spirit. After evaporation of the solvent in a
stream of nitrogen, the residue was dissolved in toluene
and the fatty acids were esterified with 2% H2SO4-metha-
nol at 80°C for 2 h. The methyl esters of fatty acids were
extracted into petroleum spirit. The fatty acids were ana-
lysed with Hewlett-Packard 5890A gas chromatograph
equipped with a flame ionisation detector using a Nor-
dion NB 351 capillary column (25 m, 0.32 mm I.D., 0.20
μm).
Data analysis
Results are expressed as mean ± SEM. Statistical compari-
sons were made by one-way analysis of variance using
SPSS software, version 16.0. Post hoc comparisons of
means were made using Dunnett's test. A p value < 0.05
was taken to be statistically significant.
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